Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
ALLO vs AXON: Weighing a Clinical-Stage Biotech Catalyst Story Against a Profitable Public Safety Technology Leader

ALLO vs AXON: Weighing a Clinical-Stage Biotech Catalyst Story Against a Profitable Public Safety Technology Leader

Key Takeaways

  • Allogene Therapeutics (ALLO) is a clinical-stage biotech with no marketed product, while Axon Enterprise (AXON) is a profitable public-safety technology leader with rapid revenue growth.
  • ALLO's near-term story hinges on clinical trial catalysts, particularly the ALPHA3 study and a fourth-quarter 2026 data update for its autoimmune program.
  • AXON delivered roughly 34–35% year-over-year revenue growth in recent quarters but has seen its share price decline significantly from 2025 highs as high-valuation growth stocks repriced.
  • The two names sit at opposite ends of the risk spectrum: ALLO offers binary, catalyst-driven upside, while AXON offers established cash flow with premium valuation.
  • Get more detail on each ticker's major news and daily price action on dedicated pages: ALLO Major News and ALLO Today's Price Move, as well as AXON Major News and AXON Today's Price Move.
  • To see how AI-powered trading systems are currently positioning across the market, explore Trending AI Robots.

Setting the Stage for This Comparison

Placing ALLO and AXON side by side highlights two sharply different investment profiles. Allogene Therapeutics focuses on developing off-the-shelf allogeneic CAR T cell therapies using engineered immune cells from healthy donors, while Axon Enterprise provides TASER devices, body cameras, software, and AI tools for law enforcement and public safety. This contrast matters for investors balancing high-growth, cash-generating businesses against more speculative, catalyst-driven biotech opportunities.

Allogene Therapeutics: Clinical Data and Cash Runway Shape the Outlook

Allogene Therapeutics operates as a South San Francisco-based biotech without a commercial product, so its value rests mainly on trial results and its cash position. Recent activity reflects promising early data from the ALPHA3 pivotal study of cema-cel in large B-cell lymphoma, where an interim analysis showed a 58.3% minimal residual disease negativity rate at day 45 versus 16.7% for observation, with no treatment-related serious adverse events. The company raised roughly $200 million through a public offering, extending its cash runway into 2029. Shares have posted solid year-to-date gains amid volatility, elevated short interest, and above-market beta. A fourth-quarter 2026 update on the ALLO-329 autoimmune program stands out as an important near-term catalyst, while event-free survival data remains slated for 2027–2028. I also checked this using Tickeron’s AI Trend Prediction Engine to monitor trend stability around these events.

Axon Enterprise: Strong Fundamentals Meet Valuation Pressure

Axon Enterprise delivers a broad ecosystem that includes TASER energy weapons, body-worn and in-car cameras, drones, digital evidence management, and AI-driven software. Quarterly revenue has grown roughly 34–35% year over year, with its AI Era product line expanding and future contracted bookings supporting recurring revenue strength through a high net revenue retention rate. Even so, the stock has lagged over the past year and sits well below its 2025 peak as high-multiple growth names faced repricing. The recent launch of the Axon Body 5 camera at the 2026 IACP conference drew attention, and analysts largely maintain a Buy consensus with price targets above recent levels. Forward valuation stays elevated, leaving sentiment tied to growth sustainability and margin trends.

Head-to-Head: Maturity, Risk, Momentum, and Sector Exposure

The most striking difference lies in business maturity. AXON produces billions in annual revenue, positive net income, and a growing base of recurring software revenue, whereas ALLO has essentially no product sales and relies on capital raises plus clinical milestones. Their risk profiles therefore diverge: AXON faces potential valuation compression, government budget cycles, and margin pressure on newer hardware, while ALLO contends with binary trial outcomes and possible dilution. On momentum, the stocks have moved in opposite directions recently, with ALLO showing year-to-date strength on trial optimism and AXON underperforming despite solid fundamentals. Sentiment also varies, with AXON enjoying broad analyst coverage and a Buy consensus compared with ALLO’s higher short interest and more divided views. Sector exposure adds another layer, as AXON provides defensive, recurring-revenue public-safety technology while ALLO offers speculative exposure to cell therapy and autoimmune applications.

AI Lens on Relative Positioning

Based on factors such as trend consistency, stability, and catalyst structure, Tickeron’s AI would likely view AXON as the more consistent, lower-volatility holding thanks to its established revenue base and recurring cash flows, even after the share-price correction. ALLO presents a more speculative profile that improves around clinical data releases but remains less stable and more sensitive to binary events. This assessment reflects probabilistic outcomes rather than certainties, given the distinct risk-reward profiles.

Exploring AI Trading Bots for Strategy Testing

In my research process, I often review Tickeron’s AI Trading Bots to test how automated strategies might handle names with such different risk profiles. The platform lets users examine performance across various market conditions and timeframes, which adds a useful quantitative layer when comparing holdings like these.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AXON, ALLO

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


AXON's RSI Indicator descends into oversold zone

The RSI Indicator for AXON moved into overbought territory on November 20, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 270 of 367 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 52 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 27 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.

The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 36.83B. The market cap for tickers in the group ranges from 4.49 to 1.77T. SPCX holds the highest valuation in this group at 1.77T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was -16%. For the same Industry, the average monthly price growth was -17%, and the average quarterly price growth was -35%. POWW experienced the highest price growth at 13%, while VWAV experienced the biggest fall at -55%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 41%. For the same stocks of the Industry, the average monthly volume growth was 16% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 53
Price Growth Rating: 65
SMR Rating: 78
Profit Risk Rating: 79
Seasonality Score: -14 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company

Industry AerospaceDefense

Industry
Biotechnology
Address
17800 North 85th Street
Phone
+1 480 991-0797
Employees
6300
Web
https://www.axon.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.